Friday 6 November 2026 Export IMA’s income statement to Excel — free account

ImageneBio, Inc.

IMA Healthcare Biotechnology

ImageneBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $800,000.00, down 77.1% from fiscal 2024.

Revenue: −60.1%
EPS: +85.9%
Free cash flow: +23.8%

Quarter to June 2026, against a year earlier

Insider buying

4.11 0.06 −1.44%

Follow IMA

Alert me

Market cap: $47.3M
P/E: 0.0×
Fwd P/E: −1.3×
Dividend yield: —
F-score: 3/9
Altman Z: −1.12
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 0.10

Sold, $m 0.02

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	1	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	1	—	—	—	—

Insider Ownership 55.08%

Capital & Financial Ratios $m

Size

Market Cap 47.28

Revenue ttm 6.14

Net income ttm (52.48)

Free cash flow ttm (52.59)

Net debt Q (136.15)

Valuation

P/E 0.00

Forward P/E (1.27)

Price / sales 10.81

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.47

Financial health

Current ratio Q 21.47

Debt / equity Q 0.00

Interest coverage Q (9.02)

Growth

Revenue growth Q −60.08%

Operating income growth Q −60.15%

EPS, this year +66.59%

EPS, next year A −7.95%

Revenue, next year A −66.66%

EPS, past 5 yrs —

EPS, next 5 yrs A +27.01%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 75.50%

10-year low 10-year high

P/B against its own 10 years 35.88%

10-year low 10-year high

EV/Sales against its own 10 years 37.15%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	175	12	135	136
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	179	12	140	141

	2023	2024	2025	Q'26
Payables	2	5	1	1
ST’ Debt	—	8	—	—
Other	—	—	—	—
	14	17	11	7

Compound Annual Growth %

	10y	5y	3y
Sales	—	(38.64%)	(62.86%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(3.24%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.90 Actual −0.63

−3.25 −2.51 −1.77 −1.03 −0.29

Q3 FY25 Miss −1.44

Q1 FY26 Miss −0.25

Q2 FY26 Beat +0.27

Q3 FY26 — Nov 11

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY25	−1.47	−2.91	Miss by 1.44
Q1 FY26	−0.70	−0.95	Miss by 0.25
Q2 FY26	−0.90	−0.63	Beat by 0.27
Q3 FY26	−0.83	—	Reports 11 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.95)	(0.63)	—	—	—
’25	(3.80)	(4.46)	(2.91)	(1.12)	(9.64)
’24	(3.96)	(3.36)	(2.58)	—	(22.10)
’23	(4.68)	(5.28)	(4.80)	(4.88)	(19.57)
’22	(5.64)	(6.84)	(5.76)	(4.68)	(22.81)
’21	(30.25)	(4.20)	(4.80)	0.84	(14.65)
’20	(31.39)	(22.75)	(28.09)	(109.92)	(192.15)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	1	—	—	—	1
’24	—	—	4	—	4
’23	5	2	1	1	9
’22	3	0	6	5	16
’21	3	4	4	20	31
’20	3	3	3	0	9

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(15)	(9)	—	—	—
’25	(7)	(12)	(21)	(7)	(48)
’24	(18)	(13)	13	(3)	(21)
’23	(20)	(18)	(20)	(22)	(80)
’22	(20)	(19)	(17)	(18)	(74)
’21	(13)	(16)	(18)	(13)	(60)
’20	(10)	(8)	(8)	(13)	(38)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(15)	(9)	—	—	—
’25	(7)	(12)	(21)	(7)	(48)
’24	(18)	(12)	14	(3)	(20)
’23	(20)	(18)	(20)	(22)	(80)
’22	(20)	(19)	(18)	(18)	(76)
’21	(14)	(16)	(18)	(14)	(62)
’20	(10)	(8)	(8)	(13)	(39)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	1	14	9	31	16	9	4	1	6		(3.0%)	0	0	—	(42.3%)
	Gross margin, %	—	—	0.00	0.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00		+100.0 pt	Powerpack ImageneBio, Inc.’s next three years, line by line Analysts expect revenue to shrink 42.3% a year to 2028 — slower than the −3.0% of the last 7 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	—	—	(41)	(17)	(44)	(34)	(69)	(68)	(37)	(46)	(53)		+1.6%
	EBT margin, %	—	—	(4,127.78)	(122.28)	(481.36)	(110.10)	(440.29)	(745.94)	(1,044.43)	(5,712.38)	0.00		(1,584.6) pt
	Net income	—	0	(41)	(17)	(44)	(34)	(69)	(68)	(37)	(45)	(52)		n/m
Per share, $
Per share, $	Revenue	—	—	0.03	0.38	39.92	13.29	5.18	2.63	2.93	0.16	0.00		+29.0%
	Earnings	—	—	(1.14)	(0.47)	(192.15)	(14.65)	(22.81)	(19.57)	(22.10)	(9.64)	(5.61)		+35.7%
	Cash flow	—	—	(0.32)	1.34	(164.25)	(25.85)	(24.58)	(22.94)	(17.86)	(9.82)	(3.25)		+62.8%
	Capex	—	—	0.00	0.00	(3.33)	(0.75)	(0.47)	(0.12)	0.81	0.00	0.00		n/m
	Free cash flow	—	—	(0.32)	1.34	(167.57)	(26.60)	(25.06)	(23.06)	(17.04)	(9.82)	(3.25)		+62.8%
	Book value	—	—	(1.28)	(1.71)	(438.77)	89.18	48.75	48.83	(134.48)	27.33	8.79		n/m
	Shares, m	—	—	36	36	0	2	3	3	1	5	10		(24.8%)
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	—	—	9.62	9.62	9.62	11.32	6.07	9.06	3.20	5.47	10.81		8.0
	P/B	—	—	0.00	0.00	0.00	1.69	0.64	0.49	0.00	0.25	0.47		0.4
	EV/Sales	—	—	0.54	0.54	0.54	6.43	1.19	(1.10)	13.30	(2.50)	2.71		2.4
	EV/FCF	—	—	(0.13)	(0.13)	(0.13)	(3.21)	(0.25)	0.13	(4.80)	0.33	(0.32)		(1.0)
Cash, $m
Cash, $m	Operating cash flow	—	—	(12)	48	(38)	(60)	(74)	(80)	(21)	(48)	(53)		+22.4%
	Capex	—	—	0	0	(1)	(2)	(1)	0	1	—	1		n/m
	Free cash flow	—	—	(12)	48	(39)	(62)	(76)	(80)	(20)	(48)	(53)		+22.4%
Balance, $m
Balance, $m	Working capital	—	—	16	61	138	209	139	164	(5)	129	135		+34.6%
	Net debt	—	—	44	(3)	(162)	(230)	(155)	(175)	(5)	(135)	(136)		n/m
	Shareholders’ equity	—	—	(46)	(61)	(101)	208	147	170	(161)	133	142		n/m
Returns, %
Returns, %	ROA	—	—	(395.29)	(31.54)	(34.80)	(16.39)	(32.73)	(37.42)	(46.52)	(62.04)	(38.34)		+333.3 pt
	ROIC	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(622.37)		0.0 pt
	ROE	—	—	76.17	31.34	54.47	(63.87)	(38.76)	(43.04)	989.95	225.87	(41.34)		+149.7 pt
People
People	Employees	—	—	—	—	33	67	80	43	10	15	—		(14.6%)
	Revenue/emp, $m	—	—	0.00	0.00	0.28	0.46	0.20	0.21	0.35	0.05	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2025 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PLRX Pliant Therapeutics, Inc.	$50.5M	— (loss-making)	— (loss-making)	−95.03% (below 0%: shrinking)	n/m	+68.61% (above 0%: growing)	0.00%	0.00%	Compare
HOWL Werewolf Therapeutics, Inc.	$49.6M	— (loss-making)	— (loss-making)	+256.11% (above 0%: growing)	n/m	+146.46% (above 0%: growing)	100.00%	34.09%	Compare
APLM Apollomics Inc.	$49.5M	— (loss-making)	—	—	0.00%	+76.08% (above 0%: growing)	—	—	Compare
TIL Instil Bio, Inc.	$47.4M	— (loss-making)	—	—	n/m	+68.62% (above 0%: growing)	0.00%	0.00%	Compare
IMA ImageneBio, Inc.	$47.3M	— (loss-making)	— (loss-making)	−60.08% (below 0%: shrinking)	n/m	+23.76% (above 0%: growing)	100.00%	0.00%
HYFT MindWalk Holdings Corp.	$47.1M	— (loss-making)	— (loss-making)	+19.37% (above 0%: growing)	n/m	+9.79% (above 0%: growing)	58.58%	(159.86%)	Compare
CNTB Connect Biopharma Holdings Limited Sponsored ADR	$46.1M	— (loss-making)	— (loss-making)	+296.56% (above 0%: growing)	n/m	−23.48% (below 0%: shrinking)	100.00%	(635.98%)	Compare
MREO Mereo BioPharma Group plc - Sponsored ADR	$44.8M	— (loss-making)	— (loss-making)	—	n/m	+21.02% (above 0%: growing)	0.00%	0.00%	Compare
IBIO iBio, Inc.	$44.4M	— (loss-making)	— (loss-making)	+100.00% (above 0%: growing)	n/m	−35.33% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$47.3M	—	—	+100.00%	—	+44.82%	58.58%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 30 April 2026

Ownership

Directors and executive officers, together 2.22%

Entities affiliated with OrbiMed 9.99%

Entities affiliated with BVF 9.99%

Trails Edge Capital Partners LP 9.99%

Funicular Funds, LP 9.56%

Engene Inc. 8.61%

Omega Fund VI, L.P. 7.96%

Entities affiliated with Blue Owl Capital 7.30%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

ImageneBio, Inc. (IMA) Latest News

5 Aug

Impact 4 · 9:55 AM

Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade

Impact 3 · 8:00 AM

ImageneBio Reports Second Quarter 2026 Financial Results

7 May

Impact 3 · 4:05 PM · GlobeNewswire

ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update

13 Apr

Impact 4 · 7:00 AM · GlobeNewswire

ImageneBio Announces $30 Million Private Placement

1 Apr

Impact 4 · 4:11 PM · Simply Wall St.

Image Resources NL (ASX:IMA) Is About To Turn The Corner

10 Mar

Impact 3 · 8:00 AM · GlobeNewswire

ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

10 Feb

Impact 4 · 7:00 AM · GlobeNewswire

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

31 Dec

Impact 4 · 6:39 AM · Simply Wall St.

ImageneBio Insider Confidence Rewarded, Stock Hits US$76m Market Cap

15 Nov

Impact 3 · 8:27 AM · Simply Wall St.

Here's Why We're Watching ImageneBio's (NASDAQ:IMA) Cash Burn Situation

12 Nov

Impact 4 · 7:15 AM · GlobeNewswire

ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team

25 Jul

Impact 4 · 11:00 AM

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

23 Jul

Impact 4 · 9:00 AM

Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

15 Jul

Impact 4 · 4:15 PM · GlobeNewswire

Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals

11 Jul

Impact 4 · 8:00 AM · GlobeNewswire

Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals

14 Feb

Impact 3 · 3:11 PM

Discovering February 2025's Promising Penny Stocks On US Exchanges

2 Jan

Impact 3 · 3:07 PM

US Penny Stocks To Watch In January 2025

30 Dec

Impact 4 · 12:00 PM · Zacks

Ikena Oncology (IKNA) Moves to Buy: Rationale Behind the Upgrade

24 Dec

Impact 4 · 8:58 AM · TipRanks

Ikena Oncology and Inmagene Announce Merger and Fundraising

23 Dec

Impact 4 · 12:10 PM · MT Newswires

Ikena Oncology, Inmagene Sign Merger Deal; Shares Rise

Impact 4 · 8:30 AM · GlobeNewswire

Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

13 Nov

Impact 4 · 8:08 AM · Simply Wall St.

3 US Penny Stocks With Market Caps Over $40M To Consider

9 Nov

Impact 3 · 9:47 AM · Simply Wall St.

Ikena Oncology Third Quarter 2024 Earnings: US$0.21 loss per share (vs US$0.40 loss in 3Q 2023)

7 Nov

Impact 3 · 8:30 AM

Ikena Oncology Reports Third Quarter 2024 Financial Results

8 Aug

Impact 3 · 4:15 PM · GlobeNewswire

Ikena Oncology Reports Second Quarter 2024 Financial Results

12 Jul

Impact 4 · 10:15 AM · Zacks

Best Momentum Stocks to Buy for July 12th

1 Jun

Impact 4 · 9:45 AM · Simply Wall St.

It's Unlikely That Ikena Oncology, Inc.'s (NASDAQ:IKNA) CEO Will See A Huge Pay Rise This Year

28 May

Impact 4 · 4:42 PM · GlobeNewswire

UPDATE – Ikena Oncology Announces Strategic Update

Impact 4 · 4:15 PM · GlobeNewswire

Ikena Oncology Announces Strategic Update

13 May

Impact 4 · 4:45 PM · GlobeNewswire

Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update

10 Apr

Impact 3 · 8:00 AM · GlobeNewswire

Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

ImageneBio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 30 April 2026

Ownership

ImageneBio, Inc. (IMA) Latest News

5 Aug

7 May

13 Apr

1 Apr

10 Mar

10 Feb

31 Dec

15 Nov

12 Nov

25 Jul

23 Jul

15 Jul

11 Jul

14 Feb

2 Jan

30 Dec

24 Dec

23 Dec

13 Nov

9 Nov

7 Nov

8 Aug

12 Jul

1 Jun

28 May

13 May

10 Apr

Stockrow Weekly